[go: up one dir, main page]

PE20120937A1 - Compuestos derivados de quinolina y quinoxalina como agentes antivirales - Google Patents

Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Info

Publication number
PE20120937A1
PE20120937A1 PE2011002042A PE2011002042A PE20120937A1 PE 20120937 A1 PE20120937 A1 PE 20120937A1 PE 2011002042 A PE2011002042 A PE 2011002042A PE 2011002042 A PE2011002042 A PE 2011002042A PE 20120937 A1 PE20120937 A1 PE 20120937A1
Authority
PE
Peru
Prior art keywords
oxo
alcoxy
dihydro
ilo
pyridin
Prior art date
Application number
PE2011002042A
Other languages
English (en)
Inventor
Jim Li
Ryan Craig Schoenfeld
Joshua Paul Gergely Taygerly
Vicente Fidalgo Javier De
Francisco Xavier Talamas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20120937A1 publication Critical patent/PE20120937A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: X1, X2, X3 Y X4 SON CADA UNO N, CR5; R1 ES PIRIDINILO, 2-OXO-1,2-DIHIDRO-PIRIDIN-3-ILO; 3-OXO-3,4-DIHIDRO-PIRAZIN-2-ILO, 2-OXO-TETRAHIDRO-PIPERIDIN-1-ILO, ENTRE OTROS; R2 ES H, ALCOXI C1-C6, ALQUILO C1-C6, HALOALQUILO C1-C6, ENTRE OTROS; R3 ES ARILO, HETEROARILO OPCIONALMENTE SUSTITUIDO 1-3 VECES POR HIDROXI, ALCOXI C1-C6, HIDROXIALQUILO C1-C6, ENTRE OTROS; R4 ES CF3, CH2CF3, CICLOALQUILO C3-5, HALOGENO, ALCOXI C1-6, ENTRE OTROS; R5 ES H, HALOGENO, ALCOXI C1-C6, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: N-{4-[6-TERT-BUTIL-2-METOXI-8-(2-OXO-1,2-DIHIDRO-PIRIDIN-3-IL)-QUINOLIN-3-IL]-FENIL}-METANOSULFONAMIDA; N-{(S)-1-[6-TERT-BUTIL-8-(6-HIDROXIMETIL-2-OXO-1,2-DIHIDRO-PIRIDIN-3-IL)-5-METOXI-QUINOLIN-3-IL]-PIRROLIDIN-3-ILMETIL}-METANOSULFONAMIDA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE LA POLIMERASA NS5b UTIL EN EL TRATAMIENTO DE HEPATITIS C
PE2011002042A 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales PE20120937A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18546009P 2009-06-09 2009-06-09
US26335109P 2009-11-21 2009-11-21

Publications (1)

Publication Number Publication Date
PE20120937A1 true PE20120937A1 (es) 2012-08-01

Family

ID=42288900

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001204A PE20151092A1 (es) 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE2011002042A PE20120937A1 (es) 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001204A PE20151092A1 (es) 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Country Status (24)

Country Link
US (2) US8026253B2 (es)
EP (1) EP2440528B1 (es)
JP (1) JP5612678B2 (es)
KR (1) KR101431343B1 (es)
CN (1) CN102803216B (es)
AR (1) AR077004A1 (es)
AU (1) AU2010257592B2 (es)
BR (1) BRPI1010852A2 (es)
CA (1) CA2764141C (es)
CO (1) CO6400218A2 (es)
CR (1) CR20110605A (es)
EC (1) ECSP11011513A (es)
ES (1) ES2525254T3 (es)
IL (1) IL216412A (es)
MA (1) MA33360B1 (es)
MX (1) MX2011013209A (es)
MY (1) MY157435A (es)
NZ (1) NZ596646A (es)
PE (2) PE20151092A1 (es)
RU (1) RU2540332C2 (es)
SG (1) SG176762A1 (es)
TW (1) TWI428332B (es)
WO (1) WO2010142656A1 (es)
ZA (1) ZA201108921B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201035083A (en) * 2009-03-06 2010-10-01 Hoffmann La Roche Heterocyclic antiviral compounds
JP5651239B2 (ja) * 2010-07-07 2015-01-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 複素環式抗ウイルス化合物
KR101382730B1 (ko) * 2010-08-13 2014-04-08 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
PE20151203A1 (es) 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
NZ724691A (en) * 2014-03-24 2018-02-23 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
JP2018525371A (ja) * 2015-07-30 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アリール置換された二環式ヘテロアリール化合物
EP3774804A1 (en) 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
WO2021053555A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Glue degraders and methods of use thereof
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
EP4236928A4 (en) * 2020-10-30 2024-08-28 1Cbio, Inc. ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND THEIR USES

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB558009A (en) * 1942-05-08 1943-12-15 Harold Coates Quinoline derivatives
BR9004801A (pt) * 1989-09-26 1991-09-10 Sumitomo Chemical Co Composto e processo para sua preparacao,composicao herbicida,processo para exterminar ervas daninhas prejudiciais e uso do dito composto
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AU2001261377A1 (en) * 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
PE20090994A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
PE20090995A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
MX2010002316A (es) 2007-08-29 2010-03-22 Schering Corp Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
MX2010002904A (es) 2007-09-17 2010-06-02 Abbott Lab N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
RU2543620C2 (ru) 2007-09-17 2015-03-10 Эббви Бахамаз Лтд. Производные урацила или тимина для лечения гепатита с
PL2203431T3 (pl) 2007-09-17 2012-01-31 Abbvie Bahamas Ltd Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
WO2009064852A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2009064848A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2010111437A1 (en) 2009-03-25 2010-09-30 Abbott Laboratories Antiviral compounds and uses thereof
JP5832420B2 (ja) 2009-03-25 2015-12-16 アッヴィ・インコーポレイテッド 抗ウィルス性化合物およびこの使用

Also Published As

Publication number Publication date
TW201103906A (en) 2011-02-01
PE20151092A1 (es) 2015-08-06
US8026253B2 (en) 2011-09-27
EP2440528B1 (en) 2014-10-08
NZ596646A (en) 2014-01-31
MA33360B1 (fr) 2012-06-01
KR101431343B1 (ko) 2014-08-19
CN102803216B (zh) 2016-04-06
BRPI1010852A2 (pt) 2019-09-24
JP5612678B2 (ja) 2014-10-22
ZA201108921B (en) 2014-05-28
AR077004A1 (es) 2011-07-27
HK1176070A1 (zh) 2013-07-19
US20110300103A1 (en) 2011-12-08
RU2540332C2 (ru) 2015-02-10
MY157435A (en) 2016-06-15
TWI428332B (zh) 2014-03-01
JP2012529461A (ja) 2012-11-22
CO6400218A2 (es) 2012-03-15
IL216412A (en) 2015-01-29
CA2764141C (en) 2016-11-15
CA2764141A1 (en) 2010-12-16
AU2010257592B2 (en) 2014-11-13
RU2011153788A (ru) 2013-07-20
MX2011013209A (es) 2012-01-09
ECSP11011513A (es) 2012-01-31
KR20120016675A (ko) 2012-02-24
EP2440528A1 (en) 2012-04-18
CN102803216A (zh) 2012-11-28
SG176762A1 (en) 2012-01-30
IL216412A0 (en) 2012-02-29
AU2010257592A1 (en) 2011-12-15
CR20110605A (es) 2012-02-09
ES2525254T3 (es) 2014-12-19
WO2010142656A1 (en) 2010-12-16
US20100311760A1 (en) 2010-12-09
US8487103B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20120320A1 (es) Pirazinilpirazoles
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20121431A1 (es) Derivados de pirimidina como inhbidores de la enzima cinasa ptk2
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20130155A1 (es) Derivados de ariletinilo
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20121118A1 (es) Compuestos de haloalquil heteroaril benzamida
PE20141935A1 (es) Compuestos de dioxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
PE20141120A1 (es) Compuestos heterociclicos
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
AR073136A1 (es) Compuestos de pirrol
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7

Legal Events

Date Code Title Description
FG Grant, registration